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Abstract
GATA-3 is essential for T cell development from the earliest stages. However, highly abundant
GATA-3 can drive T-lineage precursors to a non-T fate, depending on Notch signaling and
developmental stage. GATA-3 overexpression blocked pro-T cell survival when Notch-Delta
signals were present, but enhanced viability in their absence. In double-negative (DN1) and DN2
but not DN3 fetal thymocytes, GATA-3 overexpression rapidly induced mast cell lineage
respecification with high frequency by direct transcriptional reprogramming. Normal DN2
thymocytes also displayed mast cell potential, when interleukin 3 and stem cell factor were added
in the absence of Notch signaling. Our results suggest a close relationship between the pro-T and
mast cell programs and a new role for Notch in T-lineage fidelity.
INTRODUCTION
Within the hematopoietic system, the transcription factor GATA-3 is generally considered to
be T-lineage specific and essential for T cell differentiation from the earliest stages1–3.
GATA-3 is used recursively throughout T cell development (reviewed in 4) and is a master
regulator of TH2 differentiation5. When Notch-Delta signaling triggers T-lineage
differentiation from hematopoietic precursors, Gata3 is among the earliest regulatory genes
induced6,7. Thus GATA-3 is an attractive candidate for a role near the top of a T cell
specification hierarchy.
Nevertheless, several problems have complicated attempts to detect the molecular
mechanisms through which GATA-3 promotes T-lineage differentiation8–12. High doses of
GATA factors block cell cycle progression, and GATA-3 itself can be antiproliferative in
various T-lineage cells unless a hypomorphic mutant is used13–16 (T.T. et al., unpublished
data). However, a more radical possibility is that GATA-3 does not specifically instruct cells
to adopt T-lineage identity, but only supports T cell development when expressed within a
specific regulatory context. Here, we have revisited the question by asking more broadly
what instructive impacts GATA-3 may have on developing prethymic and intrathymic
lymphoid precursors when viability problems are circumvented. Both Notch-dependent and
Notch-independent roles of GATA-3 have been assessed, using the continuous monitoring
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available in monolayer culture systems with OP9 stromal cells (OP9-control) or OP9 cells
transfected with the Delta-class Notch ligand Delta-like 1 (OP9-DL1)17.
Our results show that GATA-3 does not necessarily confer T-lineage identity, but can
efficiently divert T-lineage precursors to an alternative, coherent developmental program.
The early T-lineage role of GATA-3 is thus shown to be profoundly context- and dose-
dependent. Overexpressed GATA-3 was antagonistic, not synergistic, with Notch-Delta
signaling for pro-T cell survival. Yet, elevated GATA-3 conferred the gain of a different
function, rapidly and efficiently promoting mast cell differentiation. This mast cell lineage
response is available to a high fraction of thymocytes during stages prior to the c-
KitloCD44loCD25+ (DN3) stage. In these stages the cells also retain some natural killer
(NK), dendritic, and macrophage developmental potential18–22, but we show that the
diverted thymocytes took a direct route toward mast cell differentiation quite distinct from
any of these developmental pathways. Furthermore, we show that pro-T cells with
unmanipulated GATA-3 expression also could access the mast cell differentiation pathway,
albeit at a lower frequency. The results illuminate a new aspect of the T-lineage commitment
process and reveal an unexpectedly intimate link between the T cell and mast cell
developmental programs.
Results
GATA-3 blocks initiation of T-cell development
Since GATA-3 is one of the earliest T cell specific genes induced by Notch-DL1 stimulation
of fetal liver (FL) hematopoietic precursor cells6,7, we initially tested whether GATA-3 is
the principal effector of T-lineage differentiation activated by Notch, or, whether GATA-3
promotes T cell development only in synergy with continuing Notch-Delta signals. In either
case, the kinetics of GATA-3 induction could be rate-limiting for initiation of T cell
development, and exogenous GATA-3 might either bypass the requirement for Notch
signaling or accelerate the response to it. Despite possible antiproliferative effects, any T-
lineage inducing activity should be detectable by transducing GATA-3 into purified
hematopoietic precursors, and using the OP9 culture system to track the early time course of
their differentiation in the presence or absence of DL1.
T-lineage promoting activity of GATA-3 might be seen in stem cells, accelerating them
toward a lymphoid-restricted progenitor state, or in cells that are already lymphoid-
restricted. Therefore, we tested both purified lymphoid-enriched progenitors
(Kit+Sca-1−Lin−CD27+CD135+CD127+, ‘LEP’ hereafter) and more primitive hematopoietic
precursors (Lin−Sca-1+Kit+, LSK) from FL (Fig. 1a). Both populations generated CD19+ B-
lineage cells in OP9-control culture and T-lineage cells on OP9-DL1, progressing from the
CD44+CD25− DN1 stage to the CD44+CD25+ DN2 and CD44−CD25+ DN3 stages within
about 7 days (Fig. 1b). As expected, the LEPs reached these lymphoid benchmarks more
rapidly than LSKs (Fig. 1b, compare day 2, day 7).
However, when GATA-3 was introduced using a bicistronic retroviral vector, we found that
neither prethymic precursor population showed enhanced early T-lineage differentiation
after transduction with GATA-3 as compared to empty vector controls (LZRS), using
vector-encoded EGFP expression to distinguish retrovirally transduced from nontransduced
cells. GATA-3 transduction reduced cell yield in both OP9-control and OP9-DL1 cultures
(Fig. 1c, CD45+EGFP+ relative to EGFP− cells) and blocked appearance of Thy-1+CD25+
cells. Data shown are for Bcl2-transgenic precursors, which gave better cell recovery, but
wild-type cells yielded similar results (Supplementary Fig. 1 online). In the absence of
Notch-DL1, GATA-3 was not sufficient to promote entry into the T cell pathway (Fig. 1c,
left), although the severe cell losses indicated it efficiently blocked B cell development
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(T.T., A. Arias, unpublished data). Moreover, even with appropriate Notch stimulation
(OP9-DL1), GATA-3 did not accelerate T-lineage differentiation; instead, it severely
inhibited T-lineage differentiation from both progenitor subsets. The CD44 and CD25
profiles of surviving GATA-3–transduced cells showed retarded development and cell
yields relative to LZRS-transduced cells. Therefore, in prethymic precursors, artificially
elevated GATA-3 was neither sufficient nor permissive for T-lineage initiation even in
collaboration with Notch signaling.
GATA-3 promotes thymocyte survival without Notch/DL1
Thymus entry and initiation of T cell differentiation do not protect cells from T-lineage
inhibitory effects of GATA-3 overexpression since GATA-3 transduced fetal thymocytes
were also inhibited in T-lineage differentiation on OP9-DL1 (Fig. 2a, left), confirming
results from other assays9,11. Although most cells remained Thy-1+, the yield of GATA-3
transductants and differentiation to the CD4+CD8+ double-positive (DP) stage (Fig. 2a, left
bottom) were much reduced compared to LZRS-transduced control cells. GATA-3–
transduced fetal thymocytes accumulated as DN1- and DN2-like cells with reduced CD25
expression (Fig. 2a, left). Similar developmental effects were seen using Bcl2-transgenic
thymocytes, with less impact on viable cell yield (Supplementary Fig. 2 online).
However, intrathymic precursors displayed a positive response to GATA-3 overexpression.
GATA-3 transduction enhanced proliferation and survival of thymocytes, provided that
Notch–DL1 signaling was absent. This result contrasts with unmanipulated DN1–DN3
thymocytes which require continuous Notch-Delta interaction7,20. GATA-3 transduced
thymocytes consistently expanded less than LZRS control transductants on OP9-DL1, but
substantially more on OP9-control (Fig. 2a, right top; Fig. 2b). Furthermore, the cells
increased in size (Fig. 2c, right), and included a subset with remarkably high c-Kit
expression (Fig. 2c, right). These c-Kithi cells did not express myeloid markers and differed
from normal c-Kit+ thymocytes, lacking both Thy-1 and CD27 (Fig. 2c), a marker normally
coexpressed with c-Kit on intrathymic progenitors7,23–25.
c-KithiCD27− cells were also seen among the survivors of GATA-3 transduced FL cells (not
shown), but the survival advantage of GATA-3 transduced thymocytes in the absence of
DL1 contrasted with the poor survival of GATA-3–transduced FL precursors under the same
conditions. T-lineage priming or B-lineage inhibition by Notch-Delta signaling could
underlie the difference (Fig. 2d), since a 5-day pre-culture of c-Kit+CD27+Lin− FL
precursors in ‘T-lineage conditions’ (OP9-DL1), prior to LZRS or GATA-3 transduction,
generated a population that responded to GATA-3 similarly to freshly isolated fetal
thymocytes (compare Fig. 2a, Fig. 2d bottom). If returned to T-lineage conditions (OP9-
DL1) after transduction, GATA-3 overexpression again severely reduced the frequency of
EGFP+ cells and blocked T cell development. But, the frequency of GATA-3 transduced
cells increased and c-Kit+CD27− cells were efficiently generated if the cells were cultured in
the absence of Notch signaling after this priming step (Fig. 2d).
The ability of GATA-3 to inhibit growth in the presence of DL1 and to promote growth of c-
KithiCD27− cells in the absence of DL1 was similar to the effects of the known, essential
mast cell factor GATA-2 (refs. 26–28), ectopically expressed in thymocytes (Supplementary
Fig. 2). However, c-Kithi cell emergence did not depend on T-lineage inhibition directly, for
the two effects could be separated. The hypomorphic KRR mutant of GATA-3 (refs.
15,16,29) was much less inhibitory of T cell development on OP9-DL1 than wild-type
GATA-3 or GATA-2 (Supplementary Fig. 2; data not shown). However, it was equally
effective at generating c-KithiCD27−Thy-1− cells from thymocytes in the absence of DL1
(Supplementary Fig. 2). Furthermore, the KRR mutant induced this developmental change
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through gene expression effects closely matching those of wild-type GATA-3, described
below (Supplementary Fig. 3 online).
GATA-3 redirects thymocytes to the mast cell lineage
The unusual c-Kithi population generated by GATA-3-transduced thymocytes was
characterized further. To confirm whether c-Kithi cells can be derived from cells that have
already initiated T-cell differentiation (Thy-1+), C57BL/6 fetal thymocytes were transduced
overnight with LZRS (Fig. 3a) or GATA-3 (Fig. 3b), and Thy-1+GFP+ and Thy-1−GFP+
cells were then sorted and placed in OP9-control culture. After 5 days, the cultured samples
were resorted to separate different stages of response to GATA-3, based upon Thy-1 and c-
Kit expression (Fig. 3a,b, right). GATA-3 transduction caused c-Kithi cells to emerge from
both Thy-1+ (populations D, E) and Thy-1− precursors (population G). To test whether these
c-Kithi cells correspond to stem or multipotent progenitor cells, mast cells, or other
hematopoietic cells, sorted populations denoted by A, B, C, etc. were tested in colony-
forming assays (Table 1), mast cell culture conditions (Table 1, Fig. 3c–e), and gene
expression analysis (below).
GATA-3-transduced thymocytes acquired de novo the abilities to form colonies in
methylcellulose (Table 1) and to proliferate extensively in mast cell culture conditions
containing interleukin 3 (IL-3) and stem cell factor (SCF; Table 1). These new growth
properties were acquired whether cells were originally Thy-1− or Thy-1+ (DN2 stage or
later) at transduction, but were confined to those cells that had upregulated c-Kit by day 5 in
response to GATA-3 (populations D, E and G in Table 1). LZRS-control transduced
thymocytes after 5 day OP9-control coculture (populations A, B in Table 1) could not form
colonies or grow detectably in mast cell cultures, and a distinct GATA-3–transduced
Thy-1+c-Kit− subset (population C in Table 1) also could not grow in these conditions. The
c-Kit+ GATA-3-transduced cells grown for approximately 2 weeks in mast cell culture
conditions morphologically and phenotypically resembled large and granular c-Kit+FcεRIα+
bone marrow-cultured mast cells (BMMCs) (Fig. 3c–e), distinct from normal thymocytes
(Fig. 3f).
Pathway for thymocyte respecification by GATA-3
Mast cell lineage respecification by GATA-3 began immediately after transduction with
GATA-3 (Fig. 4a,b). c-Kit upregulation began within one day after transduction, with and
without Notch-DL1 signaling (Fig. 4a), whereas most empty-vector controls lost c-Kit while
retaining CD27 expression, consistent with T-lineage identity. Distinct c-
KithiCD27loThy-1lo cells emerged from GATA-3-transduced cultures by day 3 with or
without Notch-DL1 signaling, but more efficiently in its absence (Fig. 4a, red arrows).
Further expansion of this c-KithiCD27lo population depended on DL1 absence.
In addition to c-Kit, GATA-3 upregulated expression of a full battery of mast cell
specification genes within the first day. Such expression occurred without cell death in Bcl2-
transgenic thymocytes and whether or not Notch signals were present (Fig. 4b). After
transduction and 1 day OP9-control or OP9-DL1 co-culture, GATA-3 transduction caused
~30x elevation of Gata3 RNA, and resulted in rapid upregulation of Gata1 and Gata2 (Fig.
4b, blue vs. pink bars). Notably, however, endogenous Gata3 was not upregulated by
GATA-3 (see Discussion). In addition to Gata2 and Gata1, two other transcription factor
genes required by mast cells, Mitf and Tal1 (encoding transcription factor SCL), were also
upregulated by GATA-3, as was the mast cell effector gene, carboxypeptidase (Cpa3). At
the same time, pro-T cell transcription factor genes (Tcf7, encoding transcription factor
TCF-1, and Lef1) and effector genes (Il7ra, Rag1) were downregulated. These changes did
not reflect dedifferentiation or reversion toward a common myeloid precursor state, because
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Sfpi1 (PU.1), a key determinant of myeloid potential in DN1 and DN2 pro-T cells, was
initially downregulated by GATA-3 rather than upregulated (Fig. 4b). These early effects on
T cell gene expression were remarkably selective. Numerous pro-T cell genes were
relatively unaffected by GATA-3 overexpression at this time point, in the presence or
absence of DL1 (Fig. 4b and Supplementary Fig. 3). These include Cd3e and Cd3g, Lat and
genes encoding the transcription factors Myb, Ets, Ikaros, Gfi1, and bHLH E-proteins, all of
which are rapidly downregulated when thymocytes are diverted to the myeloid or dendritic
cell pathways30.
Notch-DL1 signals moderated GATA-3 effects on many of its targets (Fig. 4b, dark blue vs.
light blue bars). Several pro-T cell genes require continuous Notch signals to maintain their
expression, but in most cases there was no evidence for interaction between GATA-3 and
the Notch effects (Supplementary Figs. 3, 4 online). Notch1, Notch3, and Notch targets
Deltex1 and Nrarp, as well as pro-T genes, Ptcra (encoding pre-TCRα) in particular,
required continuing Notch-Delta signaling for expression, with few or no GATA-3 effects in
either condition (Fig. 4b and Supplementary Figs. 3, 4). However, the Notch target gene,
Hes1, was upregulated by GATA-3 and fully protected by GATA-3 from downregulation if
Notch signals were withdrawn (Fig. 4b, dark red vs. dark blue bars; Supplementary Fig. 3).
The upregulation of mast cell associated genes by GATA-3 appeared to be independent of
mast cell cytokine signaling, as it occurred rapidly in the absence of exogenous IL-3 and
was unaffected by addition of SCF (Supplementary Fig. 4). The immediate onset of these
effects implies that GATA-3 itself was responsible, rather than the GATA-2 it can induce,
since absolute amounts of GATA-2 at this time point remained relatively low
(Supplementary Fig. 3). Thus, it appears that GATA-3 overexpression can directly and
rapidly impose a new regulatory program in developing thymocytes.
Establishment of mast cell gene expression program
The initial gene expression changes after 1 day in culture progressively intensified over the
next four days in OP9-control culture, specifically in cells that went on to express high
amounts of c-Kit. The gene expression of cell populations obtained from 5 day OP9-control
cultures was measured by quantitative RT-PCR (Fig. 4c), revealing specific differences
between those GATA-3-transduced cells that were able to divert to the mast cell lineage (D
and E, in gray boxes) and those which were unable to divert despite GATA-3 transduction
(C), or LZRS-transduced controls (A and B; see Fig. 3 for populations). Day 5 effects were
also compared with gene expression changes in GATA-3 transduced cells after a further 2
weeks of culture, either in Methocult (‘Colonies’) or in mast cell cytokines IL-3 and SCF
(‘MC culture’), in which the cells fully convert to mast cell phenotype (cf. Fig. 3c, e, f).
Because of the large dynamic range of effects, the results are displayed as the absolute gene
expression obtained in these samples measured relative to β-actin, with gene expression in
normal E14.5 fetal liver, fetal thymocytes, and bone marrow-derived mast cells (BMMC)
shown for reference (Fig. 4c).
By day 5, mast cell transcription factor genes Gata1, Gata2, Mitf and Tal1, and effector
gene Cpa3, were all upregulated in the c-KithiThy-1− subset (Fig. 4c, light blue) to
expression approaching or matching that of BMMC (Fig. 4c, black). The expression of
another mast cell-specific effector gene encoding tryptase, Mcpt6, which was not
upregulated at day 1 (Supplementary Fig. 3), also increased tremendously by this time. Mast
cell specification depends on a collaborative interaction between GATA factors and
moderate amounts of PU.1 (ref. 27), and despite the initial drop in PU.1 expression, c-Kit+
GATA-3 transductants stabilized PU.1 expression similar to or approaching that of BMMCs
at this time point (Fig. 4c). c-Kit+ GATA-3 transductants also matched mast cells, rather
than myeloid or erythro-megakaryocytic cells, in their low expression of C/EBPα (Cebpa),
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hemoglobin β (Hbb-b1), Tpo-receptor (Mpl), and Epo-receptor (Epor), and their expression
of regulatory genes such as Fog1, Fli1, c-Myb, Ets2, Runx3, and Gfi1 (Supplementary Fig. 5
online). Thus, these changes quantitatively established a mast cell-like program within 5
days in lymphoid culture conditions (Fig. 4c, light blue). Little further increase in mast cell
gene expression occurred in GATA-3-transductants grown in long-term IL-3–SCF cultures
(Fig. 4c, purple).
GATA-3 transductants with mast cell lineage potential (D, E and long-term cultures) now
lost expression of diverse pro-T cell genes in a reciprocal pattern to mast cell gene
activation, not only Tcf7 and Lef1, but also Lck, Zap70 and others, approaching the
phenotype of BMMCs. Furthermore, many Notch-dependent genes, including Ptcra, Rag1,
Deltex1, and Notch1 itself, were downregulated by culture on OP9-control due to loss of
Notch signals (Fig. 4c, Supplementary Fig. 5 online). However, GATA-3 transductants
maintained moderate expression of Notch1 as well as of the Notch-responsive gene Hes1,
even after 5-day absence of Notch–DL1 signaling, at amounts similar to those found in
BMMCs. Interestingly, among pro-T cell genes, only Cd3e expression was maintained in all
GATA-3 transductants derived from Thy-1+ cells (Fig. 4c), contrasting with its complete
absence in BMMCs. This remarkably stable Cd3e expression distinguished thymocyte-
derived mast cells from normal BMMCs, and confirmed their T-lineage origin.
Although all GATA-3 transduced cells contained similar amounts of GATA-3 mRNA, ~10x
higher than normal thymocytes (Fig. 4c, ‘GATA-3 All’), its impact on other genes
correlated with the ability or inability of each population to generate mast cells (cf. Table 1).
c-KitloThy-1+ cells (Fig. 4c, population C, dark blue) which cannot become mast cells in
long-term culture, maintained gene expression profiles most like fetal thymocytes (light
green), while gene expression patterns of c-Kit+Thy-1− cells (E, light blue) most closely
resembled that of BMMCs (black), with intermediate gene expression profiles in c-
Kit+Thy-1+ cells (D, medium blue). These results suggest variations in cell responses to
overexpression of GATA-3 (see below).
Thus, the subpopulations of GATA-3-transduced Thy-1+ fetal thymocytes that can generate
mast cells have already switched within 5 days to a gene expression profile comprehensively
matching BMMCs rather than pro-T cells. Positive upregulation of mast cell transcription
factor genes is among the earliest responses to GATA-3, providing regulatory partners that
can cooperate to enforce the lineage switch. These changes in programming are driven by
overexpression of GATA-3 before any selection in IL-3 and SCF, as summarized in
Supplementary Fig. 6 online.
Developmental window and frequency of lineage shift
To determine whether initial developmental stage differences underlie these distinct
responses to GATA-3, we purified DN1, DN2, and DN3 E14.5 C57BL/6 fetal thymocytes
and compared their responses to GATA-3 or LZRS transduction (Fig. 5). GATA-3
transduction promoted development of Thy-1loc-Kit+ cells (arrows, Fig. 5b, top) from both
DN1 and DN2 starting populations. Both yields and c-Kit intensities were substantially
higher in transductants cultured on OP9-control than on OP9-DL1. The phenotypes of
EGFP+ GATA-3 transduced cells sharply diverged from the EGFP− cells within the same
samples, which remained overwhelmingly Thy-1+ and progressed normally to c-Kit− cells
(EGFP−).
In contrast to DN1 and DN2 cells, DN3 cells failed to upregulate c-Kit after GATA-3
transduction and only responded by a partial Thy-1 downregulation on OP9-control stroma.
Both c-Kit upregulation in DN1 and DN2 cells and Thy-1 downregulation in DN2 and DN3
cells were specific effects of GATA-3 transduction (compare Fig. 5a–d). When sorted
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EGFP+ cells from the OP9-control and OP9-DL1 cultures were cultured with IL-3 and SCF,
mast cells developed and grew progressively from the DN1 and DN2 cells transduced with
GATA-3, while DN3 cells had apparently lost the ability to undergo this fate conversion
(Fig. 5a,b, numbers at right). Thus a developmental constraint, imposed between the DN2
and DN3 stages, sets the boundary for competence to transdifferentiate in response to
GATA-3. This developmental boundary, the changes in gene expression that may contribute
to it, and their relationship to Notch signaling effects are summarized in Supplementary Fig.
6 online.
The ability to be diverted by GATA-3 was common in the DN2 thymocyte population, as
shown by precursor frequency analysis (Fig. 5e). Optimal conditions for observing mast cell
conversion yielded precursor frequencies of 1/15-1/25 in GATA-3 transduced C57BL/6
DN2 thymocytes (blue curves). However, since lineage conversion entails a poorly
characterized switch in survival requirements, we also tested Bcl2-tg DN2 cells, which
showed substantially increased precursor frequencies of 1/2-1/3 (orange curves) when
transduced with GATA-3. Thus, when interim survival is not an issue, GATA-3 is highly
efficient in redirecting T-cell precursors into the mast cell lineage. Furthermore,
untransduced Bcl2-tg DN2 cells showed low, but detectable, mast cell development (green
curves).
Mast cell potential of unmanipulated thymocytes
The unexpected diversion of T cell progenitors into mast cells by GATA-3, and the observed
low frequency mast-cell development from Bcl2-tg DN2 cells, urged us to investigate mast
cell lineage potential of normal, unmanipulated thymocytes. Although known to be
uncommitted, early T cell precursors have not been shown to have mast cell potential. We
sorted the most immature fetal thymocytes, separating c-Kit+Thy-1−CD25− (pre-DN1 and
DN1-like) and c-Kit+Thy-1+CD25+ DN2 thymocytes (Fig. 6a); both demonstrated T-lineage
potential with slower or faster kinetics, respectively, corresponding to their initial
developmental stage (Fig. 6b). In the presence of Notch-DL1 signaling, no FcεRI+c-Kit+
cells developed, not even with exogenous SCF and IL-3. However, on OP9-control cells
with exogenous SCF plus IL-3 as well as IL-7, mast cells emerged within 3–4 weeks. c-
Kit+Thy-1+CD25+ DN2 thymocytes could generate mast cells as shown by phenotype (Fig.
6c) and morphology (Fig. 6d,e), but surprisingly the more primitive c-Kit+Thy-1−CD25−
thymocytes could not. Thus, even some normal fetal thymocytes possess mast cell-lineage
potential, which is repressed by Notch1-DL1 signaling. Furthermore, this potential is most
accessible in T cell precursors that have already initiated T-lineage specification, suggesting
a close relationship between the initial developmental stages of both lineages.
DISCUSSION
GATA-3 is activated in response to Notch-Delta signaling as an early and essential event in
T-lineage specification. We have shown here that GATA-3, if highly expressed, diverts
thymocytes from the T lymphoid pathway by activating a mast cell-like program,
independent of exogenous mast-cell growth factors IL-3 and SCF. Diversion occurs at the
same stages of pro-T cell development when GATA-3 is normally required for the DN1 to
DN2 transition, and is highly efficient, especially from DN2 thymocytes. Thus the positive
roles of GATA-3 for T-lineage development are intrinsically dose-dependent. Abundant
GATA-3 immediately activates mast cell regulatory and differentiation genes in pro-T cells,
and handicaps viability in the presence of Notch-Delta signaling but actively promotes
survival and proliferation when the Notch ligand DL1 is removed. Notch signals appear to
moderate GATA-3 effects in part by blunting gene expression changes and sustaining
expression of T cell genes, but also by blocking growth of cells overexpressing GATA-3.
Consistent with this, some normal, unmanipulated DN2 thymocytes also displayed mast cell
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lineage potential, but only in the absence of Notch-DL1 signaling and in the presence of
mast cell supporting cytokines.
In vivo relationships between T lineage cells and mast cells have been suggested for a long
time31, but without evidence for a definite pathway. The striking ability of mast cells to
express a broad range of ‘T-lineage specific’ cytokines, as well as GATA-3, implies some
convergence of T and mast cell programming. The T cell marker Thy-1 identifies mast cell
precursors in fetal blood, as Thy-1loc-Kithi cells displayed mast cell potential in contrast to
their Thy-1−c-Kit+ counterpart32. More recently, the thymus has been identified as a site of
mast cell development in chicken embryos33. Mast cells have also been reported in human
thymuses in pathological cases34,35, and are seen in medullary regions which are poor in
Delta-class Notch ligands36,37. Our results suggest that such mast cells could develop
intrathymically, possibly amplified in situ by a breakdown of Notch-dependent restraints.
The major regulatory pathway for normal mast-cell differentiation is not well characterized.
Balanced activity of PU.1 and GATA factors is known to be required, along with Mitf and
possibly SCL, and roles of GATA-2 and GATA-1 in this process can now be
distinguished27,38–40. However, it has remained obscure whether mast cells are ‘myeloid’ or
in a distinct class of their own. They can be derived from precursors separate from most
myeloid lineages38,41. Unlike monocyte and granulocyte lineages, but corresponding with
lymphocytes, they develop through a pathway that excludes C/EBPα42. Thus, our results
provide concrete evidence for one specific function – elevated GATA-2 or GATA-3
expression – that provides direct access to the mast cell pathway from an uncommitted, but
differentiating, lymphoid precursor. We do not propose that the thymus is a major source of
mast cells, but early developing T cells appear to be primed for mast cell development and
may provide an excellent model system to dissect distinct regulatory stages of mast cell
lineage commitment.
The mast cell lineage diversion of immature thymocytes is triggered by a factor that these
cells express normally, namely GATA-3. High GATA-3 expression may affect target genes
that can be regulated by GATA-2 in prethymic precursors, as both have similar effects.
However, our results show that differences in absolute expression level are all that is needed
to distinguish between GATA-3 contributions to the T cell lineage and GATA-3-driven mast
cell lineage diversion. The ability of some DN2 cells, expressing barely detectable GATA-2,
to differentiate into mast cells without exogenous GATA-3 suggests that their endogenous
GATA-3 expression can extend into the mast cell supporting range.
The mast cell program only seems accessible to DN1 and DN2 stage thymocytes, which also
preserve latent NK and dendritic cell or even macrophage developmental potentials. This
finding raises the question whether lineage plasticity depends on initial retrogression to
some common myeloid-lymphoid precursor state before adopting any of these alternative
fates. If so, then the mast cell reprogramming would be an instance of this general
lymphomyeloid plasticity43. In the case of the mast cell versus monocyte or dendritic cell
alternatives, however, this possibility can be excluded. Diversion of pro-T cells to these
different pathways can be triggered synchronously by elevating GATA-3 or PU.1,
respectively, making it possible to compare the programs of regulatory change. The time
courses of gene expression effects (compare ref.30) show that the two paths are completely
distinct.
In the case of PU.1-mediated monocytic-dendritic respecification, most early effects are
broadly to inhibit pro-T cell gene expression, including genes that encode signaling kinases
and transcription factors Myb, HES-1, Gfi1, bHLH factors, and Ets factors as well as
TCF-1; Gata3 is not substantially affected30. PU.1 in this context upregulates its own
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expression, along with weak upregulation of Id2 and a few myeloid genes that are much
more strongly induced later30. In contrast, the dominant GATA-3 effect is the immediate
upregulation of mast cell associated genes, including Gata2, long before most T-lineage
genes are downregulated. GATA-3 upregulation has no effect whatsoever on Myb, Gfi1, or
Ets factor genes, and acts as a positive regulator of Hes1, while transiently downregulating
PU.1. The early upsurge of GATA-2, Mitf, and GATA-1 expression provides regulatory
partners that may assist or replace GATA-3 for expression of later mast cell gene products,
such as tryptase. Thus, GATA-3 immediately redirects immature thymocytes to a mast cell
state without ‘crossing paths’ with the monocyte-dendritic programs controlled by PU.1 and/
or C/EBPα30,44. In fact, the transient repression of PU.1 in GATA-3-transduced DN1 and
DN2 cells may be important to block access to the monocyte or dendritic alternatives until
the new regulatory state is established. Thus the mast-cell pathway, accessible to a few DN2
thymocytes naturally and to a large fraction of them when GATA-3 is elevated, represents a
qualitatively distinct, additional option for pro-T cells.
Notch-Delta signaling restrains pro-T cell access to the mast-cell pathway. We show that
Notch-Delta signaling enforces a survival penalty on pro-T cells overexpressing GATA-3,
which is only partially counteracted by Bcl2 expression. At lower, endogenous expression
abundance of GATA-3, in contrast, Notch and GATA-3 are jointly required for pro-T cell
viability (D.D. Scripture-Adams and E.V.R., unpublished data). Notch-Delta signaling also
blunts, but cannot prevent, the upregulation of mast cell genes by highly abundant GATA-3
expression. These antagonistic Notch effects on high GATA-3 activity are not mediated by
HES-1 (cf. ref. 45), because GATA-3 upregulates Hes1 independently of Notch. HES-1 can
promote precursor expansion46, and it is possible that the selective upregulation of Hes1 by
GATA-3 contributes to its ability to enhance cell growth in the absence of Notch signaling.
Other Notch-induced mediators must be responsible for penalizing GATA-3 overexpressing
cells.
If a substantial increase in GATA-3 can reveal mast cell potential in DN1 and DN2
thymocytes, then the mechanisms normally restricting GATA-3 abundance in vivo must be
robust to keep this potential obscured. However, each of the hematopoietic GATA genes has
positive autoregulation potential, including GATA-3 itself in peripheral T cells47–49, and
presumably GATA-3 activates GATA-1 and GATA-2 in our studies by acting through their
autoregulatory target sites. In pro-T cells, then, GATA-3 itself must be prevented from
positive autoregulation, and our gene expression analysis supports this notion. The positive
roles of GATA-3 in T-lineage differentiation may therefore depend paradoxically on
damping functions that prevent autoactivation and thus maintain the uniquely balanced
regulatory state of T-lineage precursors.
T-lineage commitment, at the DN3 stage, coincides with an increase in GATA-3 expression
at the RNA level22, as GATA-3 is required for β-selection50, while the cells lose sensitivity
to the mast cell diversion activity of GATA-3. The ‘window’ for susceptibility to diversion
is likely to depend on specific gene regulatory features of DN1 and DN2 fetal thymocytes
such as the persistence of PU.1 or SCL. In any case, our results suggest that diversion
depends on the ability of GATA-3 to rapidly upregulate Gata2, Scl/Tal-1 and Mitf. The T-
lineage commitment process may therefore result from increasing restrictions on the
accessibility of genes like these to activation, or reactivation, during a stage when high
GATA-3 activity becomes vital for a new, TCR-dependent role.
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METHODS
Monoclonal antibodies and flow cytometry
Monoclonal antibodies have been described previously7,23, except for: CD19 (clone 6D5,
PE and PE-Cy5), CD127 (clone A7R34, PE-Cy5), CD135 (A2F10, PE), FcεRIα (clone
MAR-1, PE) and Sca-1 (clone D7, FITC), all from eBioscience. For detection of
biotinylated antibodies, streptavidin-AlexaFluor405 (Invitrogen) was used. Stainings were
performed after blocking Fc receptors as described7,23. Cell sorting was done on a
FACSVantage SE or FACSAria (Becton Dickinson Immunocytometry Systems [BDIS]) and
analysis on a FACSCalibur (BDIS). Data was acquired and analyzed using CellQuest Pro or
Diva (BDIS) or FlowJo (TreeStar Inc.) software. All fluorescence is plotted on a four-
decade logarithmic scale with forward scatter and cell numbers on a linear scale.
Fetal tissues
Embryonic day 14–14.5 C57BL/6, (C57BL/6xDBA/2)f1 (BDF1) and Eμ-Bcl2–25 (Bcl2-tg)
mouse embryos were generated from our colony30 or obtained from the Caltech Genetically
Engineered Mouse facility. FL cells were depleted for lineage marker-positive cells as
described7,23. Fetal thymus tissues were mechanically disrupted using a dounce
homogenizer and the resulting cell suspension was filtered prior to staining. All animal
protocols were reviewed and approved by the California Institute of Technology Institute
Animal Care and Use Committee.
Retroviral gene transfer
GATA-3 and GATA-3-KRRm were inserted into the bicistronic LZRS retroviral vector
containing an IRES-GFP and packaged using the Phoenix-Eco packaging cell line as
described elsewhere15. Viral supernatant was collected and stored in aliquots at −70 °C until
use. Transduction conditions were essentially as described7,23. Briefly, non-tissue culture
plates (24 or 96-well, Corning) were coated with 24 μg/ml retronectin for 2 h at 20–25 °C,
then blocked with 2% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for
30 min and incubated with retroviral supernatant for 4 h at 37 °C. After coating, viral
supernatant was removed and cells were added immediately in OP9 coculture medium as
described7,23, always containing 5 ng/ml of Flt3L and IL-7. Cells were then cultured on the
virus-coated plates overnight (15–20 h) for transduction.
Cell culture conditions
Conditions for OP9-DL1 and OP9-control stromal cocultures have been described in
detail7,23. All cytokines were from Peprotech and all tissue culture media were from
Invitrogen except as indicated. Differentiation cultures contained 5 ng/ml each of Flt3L and
IL-7, except for specific OP9 cocultures in which Flt3L was replaced by SCF (5 ng/ml), as
indicated. In some experiments, substitution of SCF for Flt3L enhanced the detection of c-
Kit+ cells over a 5-day period, but this appeared to reflect enhanced survival as it had no
detectable effect on the initial gene expression changes induced by GATA-3 (Fig. 4,
Supplementary Fig. 4). Several different culture conditions were used for the generation of
mast cells from pro-T cells. In experiments with sorted DN subsets (Fig. 5a–d), after OP9
culture GFP+ sorted cells were cultured in 50 ng/ml IL-3 and 20 ng/ml SCF. For limiting
dilution analysis (Fig. 5e) transduced or mock-transduced DN2 cells were sorted directly
onto OP9-control cells with 5 ng/ml IL-7 plus 50 ng/ml IL-3 and 20 ng/ml SCF. Medium
plus IL-3 and SCF, but not IL-7, was replaced after 1 week. For the generation of mast cells
from normal thymocytes, cocultures contained 5 ng/ml of Il-7 and Flt3L or contained SCF
(20 ng/ml) and IL-3 (50 ng/ml) with IL-7 and Flt3L. In this case, IL-7 and Flt3L were
omitted from the cultures after 2 weeks. Methocult GF M3434 (StemCell Technologies),
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containing SCF, IL-3, IL-6, and EPO, was used for colony-forming assays, according to the
instructions of the manufacturer, with 10 – 25 × 103 cells of sorted transduced fetal
thymocytes or 100 – 250 × 103 BM cells. Colonies were counted after 9 – 14 days of
culture. Cells were harvested for RNA analysis by vigorously pipetting the semi-solid
cultures with 10 ml of unsupplemented DMEM medium followed by centrifugation. For
mast-cell-culture from Thy-1 and c-Kit sorted cells (Fig. 3), after 5 day coculture with OP9-
control cells plus IL-7 and Flt3L, 10 – 100 × 103 sorted transduced fetal thymocytes or 105
BM cells were placed in DMEM supplemented with 10% fetal bovine serum, penicillin,
streptomycin, L-glutamine, mixed 9:1 with WEHI-3B cell (ATCC) conditioned medium as a
source for IL-3, plus 5 ng/ml SCF. Medium and cytokines were replaced after 7 days.
RNA extraction and quantitative real-time RT-PCR
Sorted cells were placed in 500 μL of Qiazol (Qiagen) and stored at −80 °C. RNA was
extracted using RNeasy RNA isolation kits (Qiagen) and reverse transcribed into cDNA
using Superscript RT II or III (Invitrogen). Real-time PCR reactions were performed using
SYBRGreen Universal Master Mix on a GeneAmp 7700 sequence detection system
(Applied Biosystems) with primers synthesized by Operon published previously22,23,30 plus
additional primers provided in Supplementary Table 1. Relative expression was calculated
for each gene by the ΔCt method using β-actin for normalization. Standards were BMMC
and unmanipulated E14.5 C57BL/6 fetal liver (FL) and fetal thymus.
Statistical methods
Geometric means and standard deviations were calculated using Microsoft Excel.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Inhibition of T-lineage specification of prethymic precursors by forced expression of
GATA-3
(a) Lin−Sca1+Kit+ (LSK) and Lymphoid Enriched Progenitor (LEP) cells were isolated
from E14.5 BDF1 Lin− FL precursors as indicated. (b) FACs analysis comparing the
differentiation kinetics of FL LSKs and LEPs after 2 or 7 days of OP9 coculture, showing
pro-T cell development, based upon CD44 and CD25 expression, on OP9-DL stroma and B
cell development, based on CD19 expression, on OP9-control stroma. (c) FACs analysis
comparing Bcl2-tg LSK or LEP cells transduced with empty vector control (LZRS) and
GATA-3 (GATA-3) cultured on OP9-control and OP9-DL1 cells. Transduced EGFP+ cells
were gated and analyzed for the presence and relative percentages of T-lineage specified
cells (CD25+Thy-1+) after 6 days in OP9-control cultures, or after 5 days in OP9-DL1
cultures. Results shown here and for sorted precursors without the Bcl2 transgene
(Supplementary Fig. 1 online) are representative of at least 5 additional experiments using
unsorted precursors, with and without the Bcl2 transgene.
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Figure 2. GATA-3 overexpression inhibits fetal thymocyte differentiation but enhances growth
and non-T lineage diversion in the absence of Notch/DL1 signaling
(a) Development of C57BL/6 E14.5 fetal thymocytes after transduction with GATA-3
(GATA-3) or empty vector control (LZRS) following 5d of culture with OP9-DL1 or OP9-
control stroma. FACs plots show the gated percentages of transduced EGFP+CD45+ cells
and quadrant statistics for subsets within the EGFP+CD45+ gate. These results are
representative of more than six independent experiments with fetal thymocytes from
wildtype, Bcl2-transgenic, or Rag-deficient genotypes, except that viability losses were
minimized with Bcl2-transgenic cells. (b) EGFP+ cell recovery from LZRS-control or
GATA-3 transduced fetal thymocytes split to parallel cultures in the absence (OP9-control)
or presence (OP9-DL1) of Notch signaling, after 5 or 6 days in the indicated culture
conditions. Results shown are geometric means from 2 representative experiments shown on
a log scale; error bars indicate range. (c) Size and EGFP expression of LZRS or GATA-3
transduced BDF1 E14.5 fetal thymocytes after 1 or 2 weeks of culture on OP9-control, and
surface expression of hematopoietic lineage markers by the EGFP+ cells after 2 weeks of
culture. (d) Responses of FL precursors precultured with OP9-DL1 before transduction with
GATA-3. c-Kit+CD27+Lin− FL precursors were cocultured for 5 days on OP9-DL1, then
transduced with LZRS or GATA-3 and replated on either OP9-control or OP9-DL1 cells for
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6 additional days of coculture. FACs plots show FSC versus EGFP expression immediately
after infection (upper panels) and after OP9-DL1 or OP9-control coculture (lower panels),
with the phenotypes of the EGFP+ cells. Arrows indicate c-Kithi CD27lo cells.
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Figure 3. GATA-3 redirects Thy-1+ thymocytes to the mast cell lineage
Freshly isolated E14.5 C57BL/6 fetal thymocytes were transduced overnight with (a) LZRS
and (b) GATA-3 and immediately sorted into GFP+Thy-1+ and GFP+Thy-1− populations
(blue boxes) followed by coculture with OP9-control cells. After 4 days cells were re-sorted
based on expression of CD45, GFP, c-Kit and Thy-1 (red boxes, populations labeled A–G),
which were subsequently characterized further in colony-forming assays (Table 1), mast cell
culture conditions (panels c–d; & Table 1) and gene expression analysis (Fig 4c). LZRS
controls, lacking c-Kithi cells, were sorted based upon CD45, GFP and Thy-1. Results
shown are representative of two independent complete experiments. (c) Phenotypic analysis
comparing GATA-3 diverted fetal thymocytes from population D (green lines), and
BMMCs (blue solid histograms) after 2 wk culture in mast cell conditions, including IL-3
and SCF, with normal untreated adult thymocytes (red solid histograms). GATA-3 diverted
thymocytes are more similar to BMMCs than normal thymocytes, displaying large size
(FSC), and high granularity (SSC) and expressing high amounts of surface c-Kit and
FcεRIα. (d–e) Histological staining of GATA-3 transduced fetal thymocytes (population D)
cultured for 2 weeks in mast cell conditions and stained with (d) Giemsa and (e) a mast cell
granule-specific stain, toluidine blue. (f) For comparison, normal fetal thymocytes stained
with Giemsa.
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Figure 4. Kinetics of thymocyte reprogramming by GATA-3
(a) Kinetic analysis of differentiation of Bcl2-tg thymocytes transduced overnight with
LZRS and GATA-3 and cocultured on OP9-control and OP9-DL1 cells with IL-7 and SCF.
c-Kit and CD27 expression are shown for CD45+GFP+ cells, after 1, 3 and 6 days of culture.
Arrows indicate c-Kithi CD27lo cells. Results are representative of two independent
experiments. (b) Initial gene expression changes in the first day after GATA-3 transduction
of Bcl2-tg thymocytes. Quantitative real-time RT-PCR analysis of gene expression in GFP+
CD45+ transductants following 1 day of coculture with OP9-control or OP9-DL1 stroma
(~40 hr overall). Data shown are the pooled average of the 4 samples derived from two
independent experiments (see Supplementary Figure 4 online) with error bars indicating
standard deviations. Results are normalized to β-actin and expressed on a log scale as ratios
relative to LZRS controls with OP9-DL1. (c) Distinct gene expression effects of GATA-3 in
transductants undergoing or resisting diversion. Gene expression analysis of C57BL/6
thymocyte populations 5 d after transduction from OP9-control coculture, as shown in Fig.
3a and b. LZRS transduced Thy-1+ and Thy-1− cells (LZT+, LZT−: populations A, B) are
compared with distinct subsets of GATA-3 transductants from Thy-1+ cells (G3T+:
populations C, D, E), and GATA-3 transduced Thy-1+ cells expanded in mast cell culture
(MC culture) or in Methocult colony-forming assays (Colonies). T, Thy-1; K, Kit; gray
boxes indicate GATA-3-diverted samples. Reference standards: FL (dark green), fetal
thymocytes (light green), and BMMCs (black). Geometric means from two independent
experiments are shown on a log scale in units relative to β-actin, with error bars indicating
one standard deviation.
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Figure 5. Developmental boundaries and frequency of GATA-3 mediated lineage diversion
(a–d) Development of sorted DN subsets. C57BL/6 DN1, DN2 and DN3 fetal thymocyte
populations were sorted and then transduced overnight with GATA-3 or LZRS control.
Samples were split for culture on OP9-DL1 or OP9-control stroma and analyzed after 5
days. Results are shown for GATA-3 transduced cells cocultured with OP9-DL1 (a) or OP9-
control cells (b), and LZRS transduced cells on OP9-DL1 (c) or OP9-control (d). All dot
plots are gated for CD45+, and sub-gated for GFP− and GFP+ cells. Red arrows indicate the
c-Kit+Thy− cell population. Numbers to the right of panels in (a) and (b) show the
subsequent expansion (output/input cell numbers) of these populations 2 weeks after transfer
to OP9-free culture with IL-3 and SCF. Results presented are one of two independent
experiments with similar results. (e) Frequency of mast cell precursors in GATA-3
transduced DN2 fetal thymocytes after 10 day OP9-control coculture with IL-7, IL-3 and
SCF. Limiting dilution analysis of GATA-3 transduced C57BL/6 DN2 (blue curves) and
Bcl2-tg DN2 (orange curves) fetal thymocytes, showing the log fraction of cultures negative
for mast cells. Untransduced Bcl2-tg DN2 fetal thymocytes (green curves) show very low,
but detectable, mast cell development. Data are from 2 independent experiments.
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Figure 6. Mast-cell lineage potential of normal, unmanipulated fetal thymocytes
(a) c-Kit+Thy-1−CD25− and c-Kit+Thy-1+CD25+ C57BL/6 E14.5 fetal thymocytes were
sorted as shown. (b) T-cell developmental potential of c-Kit+Thy-1−CD25− and c-
Kit+Thy-1+CD25+ C57BL/6 fetal thymocytes cultured on OP9-DL1 stromal cells for 8 days.
Both fractions include genuine T-cell precursors as both can give rise to CD4+CD8+ double
positive thymocytes on OP-DL1 with slightly different kinetics corresponding to their initial
developmental stage. (c) Flow cytometric analysis of mast cell generation from c-
Kit+Thy-1−CD25− and c-Kit+Thy-1+CD25+ C57BL/6 fetal thymocytes on OP9-control and
OP9-DL1 stromal cells in the presence of IL-7 and Flt3L, with or without the addition of
SCF and IL-3. Dot plots show FcεRI and c-Kit surface expression on CD45+-gated cells. (d)
Wright-Giemsa staining of freshly isolated sorted c-Kit+Thy-1+CD25+ thymocytes from
panel a that were used for culture experiments. (e) Wright-Giemsa staining of sorted
FcεRI+c-Kit+ cells, generated from c-Kit+Thy-1+CD25+ fetal thymocytes on OP9-control
stromal cells, after 4 weeks of culture as shown in panel c. Data are representative of two
independent experiments.
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